login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

FDA clears first ever bi-directionally retrievable vena cava filter from Crux Biomedical


Thursday, 19 Jul 2012 11:17
Tom Fogarty
Tom Fogarty


The US Food and Drug Administration (FDA) has cleared Crux Biomedical’s inferior vena cava filter with bi-directional retrieval for the prevention of pulmonary embolism. This feature allows retrieval of the device from the femoral or jugular veins, a key consideration when access to one or the other vein is limited.


“Crux designed a device that is both more versatile and simple to use,” said Tom Fogarty, cardiovascular surgeon and founder of Crux Biomedical. “Bi-directional deployment and retrieval are extremely helpful in situations where access to either the femoral or jugular vein is not possible. The Crux vena cava filter with its innovative design and materials represents a paradigm shift in prevention of pulmonary embolisms in patients at risk.”

A recently completed pivotal trial consisting of 125 patients at high risk for pulmonary embolisms, called the RETRIEVEclinical study, was performed at 22 sites in the USA, Australia, New Zealand and Belgium. The study results were presented at the 2012 Society for Interventional Radiology (SIR) meeting.


In the study, the technical success rate of filter deployment was 98%; filter retrieval success was also 98%. The average retrieval time was 7 minutes. By the 6-month follow up of the study, no embolizations, migrations or fractures were observed.


“The Crux device demonstrated excellent deployment, retrieval and safety profile,” stated Robert R Mendes, principal investigator of the study; associate professor of Surgery, University of North Carolina; and Chief of Vascular Surgery, Rex UNC Healthcare. “The clinical study evaluation has demonstrated the Crux vena cava filter can be used safely for the prevention of recurrent pulmonary embolisms.”


“The Crux vena cava filter system is the first major design innovation in vena cava filters in some 40 years,” said Mel Schatz, CEO, Crux Biomedical. “We have been pleased with both the clinical outcomes in our pivotal clinical trial and the enthusiasm expressed by physicians using the Crux vena cava filter.” The device’s novel helical shape was designed to self-center and to conform more closely to the shape of the vena cava, as well as to reduce bends and stress that can compromise filter integrity.




Add New Comment

Related Items


Most popular


DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients
Friday, 29 Aug 2014
The multicentre, 800-patient study also demonstrated that directional atherectomy was non-inferior for treating peripheral arterial disease in patients with diabetes compared with those without ... DEFINITIVE LE study results show directional atherectomy is safe and effective in claudication and critical limb ischaemia patients

First varicose vein patient treated with FDA-approved Varithena (polidocanol injectable foam) 1%
Tuesday, 12 Aug 2014
The first varicose vein patient has been treated with Varithena, the only FDA-approved foam for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities ... First varicose vein patient treated with FDA-approved Varithena (polidocanol injectable foam) 1%

Arterial embolization works to alleviate knee pain in mild to moderate osteoarthritis
Monday, 21 Jul 2014
A small study conducted in Japan, published in CardioVascular and Interventional Radiology in July 2014, demonstrates that transcatheter arterial embolization is feasible and that it rapidly relieves ... Arterial embolization works to alleviate knee pain in mild to moderate osteoarthritis

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Is all heat the same and does catheter design matter?
Wednesday, 13 Aug 2014
Mark S Whiteley writes that it is essential that every doctor practising varicose vein surgery has a good understanding of the principles of endovenous thermoablation. Is all heat the same and does catheter design matter?

Profiles


Bien Soo Tan
Friday, 16 May 2014
Bien Soo Tan, senior consultant, Department of Diagnostic Radiology, Singapore General Hospital, S... Bien Soo Tan

James B Spies
Friday, 16 May 2014
The evolution of embolization over the past decade has been remarkable and it has fundamentally ... James B Spies

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions